Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Hochschild returns to pre-tax profit in FY24, shares surge

(Sharecast News) - Shares in precious metals miner Hochschild surged in early trading after revealing it had returned to pre-tax profit in FY24. Hochschild reported a pre-tax profit of $177.2m for FY24, a marked improvement on the prior year's $43.5m loss, while revenues grew 37% to $947.7m, principally due to a 19% increase in gold prices and a 22% improvement in silver prices.

Adjusted underlying earnings were up 54% at $421.4m, while basic earnings per share came to $0.19 each, up from the prior year's loss of $0.10 per share after exceptional items. Net debt narrowed from $257.9m to $215.6m.

FY production came to 347,374 gold equivalent ounces, with Hochschild stating it was now targeting a production range of 350,000-378,000 equivalent ounces in FY25.

As a result of its return to profit, Hochschild also reinstated its dividend payout, recommending a final dividend of $1.94 per share, totalling $10.0m.

Chief executive Eduardo Landin said: "We are pleased to announce our best financial performance for 13 years, a testament to our exceptional team and high-quality assets. Our growth strategy continues to deliver, with the addition of a record 2.8m gold-equivalent ounces of mineable resources, extending the life of all our current operations and two major growth projects are now being developed that could boost annual production by over 200,000 ounces.

"In line with our commitment to shareholder value, we are restoring our dividend and introducing a clear dividend policy, underscoring our focus on sustainable returns. Our team remains dedicated to maximising value, optimising costs, and ensuring long-term growth."

As of 0910 GMT, Hochshild shares had surged 15.22% to 221.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.